Patients with microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted ...

Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...

For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...

r.ward{at}garvan.unsw.edu.au BACKGROUND AND AIMS In this study, we prospectively examined the clinical significance of the microsatellite instability (MSI) phenotype in sporadic colorectal cancer, and ...

Findings seen in patients with microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer ...

US FDA grants breakthrough therapy designation to GSK’s Jemperli for locally advanced dMMR/MSI-H rectal cancer: London, UK Tuesday, December 17, 2024, 09:00 Hrs [IST] GSK plc an ...

The study demonstrates high concordance between next-generation sequencing-based MSI and immunohistochemistry-based MMR measurements across more than 190,000 patients "Accurate MMR assessment is ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ...

The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting ...

NEW YORK – Ideaya Biosciences said on Monday that it plans to develop a KAT6/7 inhibitor, IDE251, as treatment for breast and lung cancer patients whose tumors harbor 8p11 amplifications.